AKAO 2017 Annual Report

104 Achaogen, Inc. Consolidated Balance Sheets (in thousands except for share and per share amounts) December 31, 2017 December 31, 2016 Assets Current assets: Cash and cash equivalents............................................................................ $ 145,219 $ 118,964 Short-term investments ................................................................................ 19,572 26,912 Contracts receivable..................................................................................... 1,357 12,151 Prepaids and other current assets ................................................................. 6,367 2,189 Restricted cash ............................................................................................. 5,891 127 Total current assets ................................................................................. 178,406 160,343 Property and equipment, net.............................................................................. 14,810 3,261 Restricted cash................................................................................................... 3,855 250 Deposit and other assets .................................................................................... — 71 Total assets ........................................................................................ $ 197,071 $ 163,925 Liabilities, contingently redeemable common stock and stockholders’ equity Current liabilities: Accounts payable ......................................................................................... $ 6,862 $ 5,739 Accrued liabilities ........................................................................................ 15,441 9,698 Loan payable, current portion ...................................................................... 12,500 4,167 Deferred revenue.......................................................................................... 2,100 — Other current liabilities ................................................................................ — 104 Total current liabilities ...................................................................... 36,903 19,708 Loan payable, long-term.................................................................................... 9,457 21,110 Warrant liability................................................................................................. 9,774 13,874 Derivative liability............................................................................................. 686 602 Deferred rent...................................................................................................... 8,289 1,896 Total liabilities .................................................................................. 65,109 57,190 Commitments and contingencies (Note 7) Contingently redeemable common stock (Note 11) .......................................... 10,000 — Stockholders' equity Common stock, $0.001 par value, 290,000,000 shares authorized at December 31, 2017 and December 31, 2016; 42,515,015 and 35,638,052 shares issued and outstanding at December 31, 2017 and December 31, 2016, respectively.............................................................. 42 35 Preferred stock, $0.001 par value, 10,000,000 shares authorized and zero shares issued and outstanding at December 31, 2017 and December 31, 2016 ........................................................................... — — Additional paid-in-capital ............................................................................ 494,758 353,927 Accumulated deficit ..................................................................................... (372,838) (247,220) Accumulated other comprehensive loss....................................................... — (7) Total stockholders’ equity ...................................................................... 121,962 106,735 Total liabilities, contingently redeemable common stock and stockholders’ equity............................................................................. $ 197,071 $ 163,925 See accompanying notes to consolidated financial statements.